Most bosses are defeating shareholder attempts so far this year to tamp down their pay. The question now is whether Tesla CEO Elon Musk can do the same.
These five companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks included.
The FDA grants priority review to AstraZeneca's (AZN) Tagrisso for treating patients with unresectable, stage III EGFR-mutated lung cancer. A decision is due in the fourth quarter of 2024.